Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $11.48 to $12.02
• 50-Day Range: $8.71 to $12.04
• 52-Week Range: $7.80 to $28.09
• Volume: 376,731 shs
• Average Volume: 266,722 shs
• Market Capitalization: $649.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.25
• Consensus Rating: Buy

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $17.42 at the beginning of the year. Since then, BCAX shares have decreased by 31.7% and is now trading at $11.90.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.04.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Who are Bicara Therapeutics' major shareholders?

Top institutional shareholders of Bicara Therapeutics include Vestal Point Capital LP (9.16%), Geode Capital Management LLC (1.23%), Bank of America Corp DE (0.83%) and Schroder Investment Management Group (0.78%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/02/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bicara Therapeutics: $32.25
• High Price Target: $48.00
• Low Price Target: $8.00
• Potential Upside/Downside: +177.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.67%
• Return on Assets: -20.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.80
• Quick Ratio: 25.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.04 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 54,560,000
• Free Float: N/A
• Market Cap: $633.17 million
• Optionable: N/A
• Beta: N/A